Recruiting

Deucravacitinib

Sponsor:

Bristol-Myers Squibb

Code:

NCT06875960

Conditions

Systemic Lupus Erythematosus (SLE)

Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BMS-986165

Study Details

Brief summary:

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

Conditions

Systemic Lupus Erythematosus (SLE)

Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Study ID

NCT06875960

Start date

Feb 24, 2026

Status verified date

Sep, 2026

Completion date

Jan 31, 2028

Anticipated

Primary completion date

Jan 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria

  • Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
  • Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
  • Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.

Exclusion Criteria

  • Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason.
  • Participants must not have any evidence of active Tuberculosis (TB).
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Study Design

Enrollment

35 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Administration of BMS-986165

Interventions

BMS-986165

Specified dose on specified days

Primary outcome measure

  • Number of participants treated with BMS-986165 [ Time Frame: Up to 2 years ]

Central Contacts and Locations

Central contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286Clinical.Trials@bms.com

Locations

New York University School Of Medicine

Recruiting

New York, New York, United States, 10155

Contacts

Amit Saxena, Site 0002

646-501-7387

Oklahoma Medical Research Foundation

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Cristina Arriens, Site 0004

405-271-7805

More Information

Sponsor

Bristol-Myers Squibb

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-09-09.